Physician profile
Daniel F Goodman
NPI 1679758635
$4,510.00
in general payments reported to CMS, 2019-2025
34 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $467 · 2021: $550 · 2022: $791 · 2023: $997 · 2024: $512 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Long Term Medical Supply Or Device Loan: $501 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.22 |
| Long Term Medical Supply Or Device Loan | $501.40 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,015.91 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Carl Zeiss Meditec USA, INC. | $501.40 | 2023 | Lumera |
| Sun Pharmaceutical Industries INC. | $310.01 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $298.87 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $253.22 | 2019-2023 | |
| Allergan, INC. | $211.40 | 2019-2021 | |
| Biotissue Holdings INC. | $208.07 | 2019-2022 | |
| Dompe US, INC. | $195.68 | 2019-2024 | Oxervate |
| Sight Sciences, INC. | $155.42 | 2019-2022 | |
| Lumenis Be INC | $127.04 | 2023 | M22 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.19 | 2019-2020 | |
| Amgen INC. | $107.11 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $101.18 | 2022-2023 | Tecnis Iol, Tecnis Iol |
| Johnson & Johnson Vision Care, INC. | $99.01 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $97.02 | 2024-2025 | Xdemvy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $79.55 | 2023-2025 | Tyrvaya |
| Rxsight INC | $57.35 | 2022-2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Carl Zeiss Meditec, INC. | $54.06 | 2019-2020 | |
| Abbvie INC. | $53.98 | 2022-2023 | |
| Omeros Corporation | $49.32 | 2019 | |
| Eyevance Pharmaceuticals LLC | $48.38 | 2020-2022 | |
| Coopervision INC. | $41.89 | 2020-2021 | |
| Thea Pharma INC. | $40.77 | 2022-2023 | Iyuzeh |
| Horizon Therapeutics Plc | $38.85 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $33.82 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $31.79 | 2021 | |
| Astellas Pharma US INC | $30.89 | 2025 | Izervay |
| Optos, INC. | $27.77 | 2020 | |
| Harrow Eye, LLC | $26.71 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $22.56 | 2020 | |
| Alcon Research LLC | $22.55 | 2019 | |
| Shire North American Group INC | $20.44 | 2019 | |
| Beaver-Visitec International, INC. | $19.26 | 2021 | |
| Lombart Brothers, INC. | $16.53 | 2023 | Opd-III |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.